Please login to the form below

Not currently logged in
Email:
Password:

thyroid cancer

This page shows the latest thyroid cancer news and features for those working in and with pharma, biotech and healthcare.

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

First approved in 2015 for refractory thyroid cancer, Lenvima has subsequently been given the nod as a second-line treatment for renal cell carcinoma in combination with everolimus and has been ... A second cohort of endometrial cancer patients had an

Latest news

  • NICE reverses its rejection of Eisai’s Lenvima NICE reverses its rejection of Eisai’s Lenvima

    NICE reverses its rejection of Eisai’ s Lenvima. The cost-effectiveness watchdog has now backed the thyroid cancer treatment. ... this type of thyroid cancer, we very much welcome this decision from NICE that demonstrates that these patients are no

  • Bayer gets clinical data to support $1.5bn Loxo deal Bayer gets clinical data to support $1.5bn Loxo deal

    uncontrolled cellular growth that is evident in a wide range of tumours, including infantile fibrosarcoma, thyroid cancer and various soft tissue sarcomas, but collectively account for less than 1% of all ... In all but one cases the 17 patients have

  • Strong Tagrisso soothes AZ as US sales plummet Strong Tagrisso soothes AZ as US sales plummet

    period that could see six new drugs launched for cancer alone between 2014 and 2020 - including Lynparza and Tagrisso. ... Meanwhile in its targeted oncology portfolio AZ is also expecting to file BTK inhibitor acalabrutinib for B-cell malignancies later

  • NICE backs Eisai's Halaven for breast cancer NICE backs Eisai's Halaven for breast cancer

    metastatic breast cancer in England will finally now have routine access to eribulin". ... The company "would like the same opportunity to enable access to our newer cancer drug lenvatinib for radioiodine refractory differentiated thyroid cancer patients,

  • Eisai wins EU licence for kidney cancer drug Kisplyx Eisai wins EU licence for kidney cancer drug Kisplyx

    Analysts are now suggesting that with Kisplyx's approval in two key markets, plus its current global availability as a thyroid cancer treatment, the drug has blockbuster potential. ... We remain committed to exploring the potential of lenvatinib for

More from news
Approximately 10 fully matching, plus 48 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Ipsen paid $200m upfront for the rights (ex-North America &Japan) to commercialise Cometriq for medullary thyroid cancer and other indications. ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal

  • EATRIS and the new age of partnering EATRIS and the new age of partnering

    In a display of its global ambition, EATRIS is joining with Cancer Research UK to bring representatives of the US's National Cancer Institute to a workshop in Brussels in October ... The first one we initiated in this matchmaking process was a bio-marker

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    The company is building on its recent oncology launches of Caprelsa (vandetanib) for medullary thyroid cancer - approved in Europe in 2012 - and Iressa (gefitinib), an epidermal growth factor receptor tyrosine kinase ... 2 trials for NSCLC, and

  • Pharma deals during August 2013 Pharma deals during August 2013

    In 2012 these drugs generated $289.6m in revenue for Onyx. Included in the Onyx clinical pipeline are sorafenib (in phase III for thyroid cancer) also partnered with Bayer and carfilzomib, ... This protracted process is indicative of the now “ holy

  • Eisai: Bucking the trend with R&D growth Eisai: Bucking the trend with R&D growth

    III, this time for thyroid cancer. ... The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets. “

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...

Infographics